Oral Oxytocin's Effects on Attention Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-28

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to investigate whether orally administered oxytocin (24IU) could modulate attention control using a social-emotional saccade/antisaccade eye-tracking paradigm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Differential Effects of Oral and Intranasal Oxytocin on Attention Control

NCT04815395

Healthy

COMPLETED NA

Differential Effects of Vasopressin and Oxytocin on Attention Control

NCT04715737

Healthy

COMPLETED NA

The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )

NCT07140237

Healthy Adult Male

RECRUITING EARLY_PHASE1

The Effect of Oral Oxytocin and Atosiban on Social Attention

NCT07093060

Healhty

RECRUITING EARLY_PHASE1

The Effects of Intranasal and Oral Administration of Oxytocin on Responses to Emotional Scenes

NCT05532501

Healthy

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Numerous studies have reported the effect of intranasally administered oxytocin on attentional processing including stimulus-driven bottom-up processing and top-down goal-directed inhibitory control. However, it is unclear whether the functional effects are mediated by the peptide directly entering the brain or indirectly via raising peripheral concentrations. One possible method of producing a similar pattern of increased peripheral oxytocin concentrations but without the possibility of direct entry into the brain would be to administer the peptide lingually. In the present double-blind, between-subject, placebo-controlled study, 80 healthy male subjects will be recruited and receive either oxytocin (24IU) or placebo control administered orally (lingual). 45 minutes after treatment subjects are required to complete a social-emotional saccade/antisaccade eye-tracking paradigm. This paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of orally administered oxytocin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral Oxytocin

Oxytocin orally (24 IU)

Group Type EXPERIMENTAL

Oral Oxytocin

Intervention Type DRUG

Administration of oxytocin orally (24 IU)

Oral Placebo

Placebo orally (24 IU, identical ingredients, except the active agent)

Group Type PLACEBO_COMPARATOR

Oral Placebo

Intervention Type DRUG

Administration of placebo orally (24 IU)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Oxytocin

Administration of oxytocin orally (24 IU)

Intervention Type DRUG

Oral Placebo

Administration of placebo orally (24 IU)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male, healthy participants
* Non smokers

Exclusion Criteria

* Previous or current medical, psychiatric, neurological disorder
* Regular medication
* Use of any psychoactive substances in the 24 hours before experiment
* Contra-indications for oxytocin
* Contra-indications for eye-tracking data acquisition

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes